We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Carlsbad, CA-based Ionis Pharmaceuticals, Inc. (IONS - Free Report) is a drug discovery and development company that focuses on the development of products using ribonucleic acid (RNA)-based technologies. The company discovers new drugs and out-licenses them to partners for license fees, milestone payments, and royalties. Ionis has partnership agreements with several leading health care companies like Biogen and GlaxoSmithKline among others.
In Dec 2016, Ionis and partner Biogen received FDA approval for Spinraza (nusinersen), an antisense drug, for the treatment of spinal muscular atrophy (SMA). This makes it the first and only treatment to be approved in the U.S. for SMA, thus allowing it to tap a market with high potential. Though this is not expected to contribute to Ionis’ fourth-quarter sale, Spinraza is expected to be a revenue driver for Ionis in 2017. Some promising pipeline candidates include IONIS-TTRRx (transthyretin amyloidosis), and volanesorsen (familial chylomicronemia syndrome and familial partial lipodystrophy) among others.
Ionis’ earnings track record has been mixed so far. Over the four trailing quarters, the company posted an average negative earnings surprise of 10.44%, having beaten estimates in one quarter and missed the same once.
Ionis’ share price decreased 2% year to date compared with the Zacks classified Medical-Medical Services industry’s gain of 4.4%.
Currently, Ionis has a Zacks Rank #3 (Hold) but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Ionis reported earnings of 21 cents including stock based compensation. However, excluding stock based compensation the company reported earnings of 33 cents that surpassed the Zacks Consensus Estimate of loss of 20 cents.
Revenues: Ionis posted revenues of $160.3 million, beating the consensus estimate of $82 million.
Key Stats: Research, development and patent expenses amounted to $101.2 million, down 0.2% year over year. General and administrative expenses increased 36.9% year over year to $18 million.
Check back for our full write up on earnings report later!
Ionis Pharmaceuticals, Inc. Price and EPS Surprise
A Full-Blown Technological Breakthrough in the Making
Zacks’ Aggressive Growth Strategist Brian Bolan explores autonomous cars in our latest Special Report, Driverless Cars: Your Roadmap to Mega-Profits Today. In addition to who will be selling them and how the auto industry will be impacted, Brian reveals 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Ionis Pharmaceuticals (IONS) Beats on Q4 Earnings
Carlsbad, CA-based Ionis Pharmaceuticals, Inc. (IONS - Free Report) is a drug discovery and development company that focuses on the development of products using ribonucleic acid (RNA)-based technologies. The company discovers new drugs and out-licenses them to partners for license fees, milestone payments, and royalties. Ionis has partnership agreements with several leading health care companies like Biogen and GlaxoSmithKline among others.
In Dec 2016, Ionis and partner Biogen received FDA approval for Spinraza (nusinersen), an antisense drug, for the treatment of spinal muscular atrophy (SMA). This makes it the first and only treatment to be approved in the U.S. for SMA, thus allowing it to tap a market with high potential. Though this is not expected to contribute to Ionis’ fourth-quarter sale, Spinraza is expected to be a revenue driver for Ionis in 2017. Some promising pipeline candidates include IONIS-TTRRx (transthyretin amyloidosis), and volanesorsen (familial chylomicronemia syndrome and familial partial lipodystrophy) among others.
Ionis’ earnings track record has been mixed so far. Over the four trailing quarters, the company posted an average negative earnings surprise of 10.44%, having beaten estimates in one quarter and missed the same once.
Ionis’ share price decreased 2% year to date compared with the Zacks classified Medical-Medical Services industry’s gain of 4.4%.
Currently, Ionis has a Zacks Rank #3 (Hold) but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Ionis reported earnings of 21 cents including stock based compensation. However, excluding stock based compensation the company reported earnings of 33 cents that surpassed the Zacks Consensus Estimate of loss of 20 cents.
Revenues: Ionis posted revenues of $160.3 million, beating the consensus estimate of $82 million.
Key Stats: Research, development and patent expenses amounted to $101.2 million, down 0.2% year over year. General and administrative expenses increased 36.9% year over year to $18 million.
Check back for our full write up on earnings report later!
Ionis Pharmaceuticals, Inc. Price and EPS Surprise
Ionis Pharmaceuticals, Inc. Price and EPS Surprise | Ionis Pharmaceuticals, Inc. Quote
A Full-Blown Technological Breakthrough in the Making
Zacks’ Aggressive Growth Strategist Brian Bolan explores autonomous cars in our latest Special Report, Driverless Cars: Your Roadmap to Mega-Profits Today. In addition to who will be selling them and how the auto industry will be impacted, Brian reveals 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>